Pharmaceuticals

Inhalable Biologics Industry Overview 2025: Growth Projections and Market Trends

November 10, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Are The Growth Projections For The Inhalable Biologics Market Size During 2025–2029?

The inhalable biologics market size has experienced rapid expansion recently. It is forecast to grow from $2.79 billion in 2024 to $3.22 billion in 2025, achieving a compound annual growth rate (CAGR) of 15.4%. The market’s growth during the historic period can be attributed to the global increase in respiratory disease prevalence, the rising demand for non-invasive delivery options, enhanced awareness of biologics’ advantages, and increased biopharma research and investment.

The inhalable biologics market is projected to experience swift expansion in the coming years, with its value anticipated to reach $5.77 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 15.7%. This growth over the forecast period can be primarily attributed to factors such as an escalating global aging population, expanding healthcare infrastructure in developing regions, increasing regulatory backing for biologics therapies, and an uptick in infectious respiratory disease occurrences. Key trends anticipated during the forecast period encompass progress in drug delivery systems, the incorporation of smart inhaler technology, technological breakthroughs in aerosol science, advancements in biologic drug formulations, and enhancements in nanoparticle-based carriers.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24253&type=smp

Which Industry Drivers Are Expected To Accelerate The Inhalable Biologics Market From 2025 To 2029?

A rise in respiratory ailments is projected to drive expansion within the inhalable biologics market in the future. These conditions encompass illnesses and dysfunctions impacting various parts of the respiratory system, including the airways, nasal passages, and lungs. The widespread occurrence of respiratory conditions stems from escalating air pollution, which exacerbates issues like asthma, chronic obstructive pulmonary disease (COPD), and lung cancer through individuals’ exposure to detrimental particulate matter and other contaminants. Inhalable biologics offer advantages for respiratory ailments because they provide precise treatment directly to the lungs, alleviating inflammation and enhancing lung function while minimizing systemic adverse effects. For example, as reported in June 2024 by the Australian Institute of Health and Welfare, an Australia-based government agency, chronic obstructive pulmonary disease (COPD) constituted 3.6% of the overall disease burden and 50% of the respiratory disease burden in 2023. Consequently, the growing number of respiratory conditions significantly contributes to the expansion of the inhalable biologics market.

How Is The Inhalable Biologics Market Segmented?

The inhalable biologics market covered in this report is segmented –

1) By Type: Peptides And Proteins, Vaccines, Monoclonal Antibodies, RNAi-Based Therapeutics, Other Types

2) By Dosage Form: Dry Powder Inhalers, Metered Dose Inhalers, Nebulizers, Other Dosage Forms

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

4) By Application: Respiratory Diseases, Diabetes, Cancer, Other Applications

Subsegments:

1) By Peptides And Proteins: Insulin, Growth Hormones, Enzyme Replacement Therapies, Other Peptides And Proteins

2) By Vaccines: Influenza Vaccines, Other Respiratory Vaccines

3) By Monoclonal Antibodies: Respiratory Monoclonal Antibodies, Immunomodulatory Monoclonal Antibodies, Other Monoclonal Antibodies

4) By RNAi-Based Therapeutics: RNA-Based Drugs For Respiratory Diseases, Other RNAi-Based Therapeutics

5) By Other Types: Gene Therapies, Small Molecule Inhalable Drugs, Other Innovative Inhalable Biologics

What Long-Term Trends Will Shape The Future Growth Of The Inhalable Biologics Industry?

Major companies operating in the inhalable biologics market are concentrating on developing innovative solutions, such as inhaled insulin, to enhance patient compliance and provide rapid glycemic control. Inhaled insulin is a type of insulin delivered into the bloodstream through the lungs by inhalation, rather than through injections or insulin pumps. This technique involves breathing in a powder or aerosolized form of insulin, which is absorbed through the lungs and quickly enters the bloodstream to aid in regulating blood sugar levels. For instance, in February 2025, Cipla Limited, an India-based pharmaceutical company, received regulatory approval from the Central Drugs Standard Control Organization for Afrezza, the world’s fastest inhaled insulin, presenting a revolutionary, needle-free choice for adults with type 1 and type 2 diabetes. This ultra-rapid-acting insulin takes effect within 12 to 15 minutes of inhalation, closely mimicking the natural insulin response to meals and improving blood sugar management. The inhaled insulin provides a more comfortable alternative to multiple daily injections, especially benefiting patients with injection anxiety and strengthening adherence to insulin therapy.

Which Key Market Players Are Investing In Expansion And Innovation Of Inhalable Biologics Market?

Major companies operating in the inhalable biologics market are Bayer AG, Sanofi SA, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Medtronic PLC, Moderna Inc., Pfizer Inc. and BioNTech SE, Teva Pharmaceuticals, Baxter International, Lonza Group AG, CanSino Biologics Inc., Cipla Ltd., Insmed Incorporated, Kamada Pharmaceuticals, Vectura Group plc, F. Hoffmann‑La Roche Ltd, Iconovo AB, Synairgen plc, Ab Initio Pharma LLC, Nanopharm Ltd, Ocugen Inc., MannKind Corporation

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/inhalable-biologics-global-market-report

Which Region Shows The Highest Potential For Future Expansion In The Inhalable Biologics Market?

North America was the largest region in the inhalable biologics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the inhalable biologics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Inhalable Biologics Market Report:

https://www.thebusinessresearchcompany.com/customise?id=24253&type=smp

Browse Through More Reports Similar to the Global Inhalable Biologics Market 2025, By The Business Research Company

Inhalation Sedative Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/inhalation-sedative-global-market-report

Inhalation Anesthesia Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/inhalation-anesthesia-global-market-report

Inhalation And Nasal Spray Generic Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/inhalation-and-nasal-spray-generic-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795